The management of patients with metastatic hormone-sensitive prostate cancer (mHSPC) has been significantly modified by the availability of innovative but expensive treatments, increasing the economic burden of prostate cancer. Here, we aimed to systematically identify and review published economic evaluations (EEs) related to the treatment of mHSPC and assess their quality. A systematic search was performed of the PubMed and Cochrane databases. Three reviewers independently selected EEs by defined inclusion and exclusion criteria. They extracted all data from each EE (general information, study population, data about the EE, interventions and comparators, and outcomes). They also assessed the quality of the selected EEs according to Drummond's checklist. Fourteen EEs published between 2016 and 2021 were eligible for the systematic review. The EEs found ADT + docetaxel to be the most cost-effective of all available treatments as a first-line strategy for mHSPC (abiraterone acetate plus prednisone, enzalutamide, and apalutamide). Five EEs showed that a simple price reduction of abiraterone acetate of 50% to 75% could change the results to render this treatment also cost-effective relative to that with docetaxel. Twelve EEs were of high quality, with a Drummond score ≥ 7. Analysis of the 14 EEs identified by our systematic review, amongst which 78.6% met high quality standards, showed that ADT + docetaxel tends to be the most cost-effective alternative for mHSPC. These results were assessed by sensitivity analysis. The data provided by this systematic review help to provide a better understanding of these treatments and the better use of healthcare resources.
Clinical genitourinary cancer. 2022 Apr 29 [Epub ahead of print]
Rémi Pelloux-Prayer, Thomas Bataillard, Antoine Thiery-Vuillemin, Alexandre Vincent, Philippe Fagnoni, Virginie Nerich
Department of Pharmacy, University Hospital of Besançon, Besançon, France., INSERM, EFS-BFC, UMR 1098, University of Bourgogne, Besançon, France; Department of Medical Oncology, University Hospital of Besançon, Besançon, France., Department of Pharmacy, University Hospital of Dijon, Dijon, France; INSERM UMR 1098, University of Bourgogne-Franche-Comté, Besançon, France; EPICAD LNC UMR 1231, University of Bourgogne, Dijon, France., Department of Pharmacy, University Hospital of Besançon, Besançon, France; INSERM, EFS-BFC, UMR 1098, University of Bourgogne, Besançon, France. Electronic address: .